Could a diabetes drug also mend hearts? new study in kazakhstan investigates
NCT ID NCT07303556
First seen Jan 04, 2026 · Last updated Jun 13, 2026 · Updated 27 times
Summary
This study tests a dual GIP/GLP-1 drug (a type of diabetes medication) in 120 adults in Kazakhstan who have both chronic heart failure and type 2 diabetes. Participants take the drug for 40 weeks and have regular heart tests, blood work, and genetic checks. The goal is to see if the drug improves heart function, blood sugar, and weight, and to understand how genetics affect response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
PI "National Laboratory Astana", Nazarbayev University
Astana, Kazakhstan, 010000, Kazakhstan
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.